EGFR and lung adenocarcinoma: The addition of β-blockers was noted to improve progression-free survival in patients with lung adenocarcinoma with EGFR mutations receiving afatinib compared to patients taking afatinib without any β-blockers, as observed in a reanalysis of a phase III clinical trial (40).